This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Distinguished as a biochemist. Was the first to show the possibility of using counter-current liquid-liquid extraction in the separation of N-acetylamino acids. In collaboration with A.J.P. Martin this led to the development of partition chromatography, which they have applied with conspicuous success in problems related to the composition and structure of proteins, particularly wool keratin. Synge's recent work on the composition and structure of gramicidins is outstanding and illustrates vividly the great advances in technique for which he and Martin are responsible. In 1963 he was elected a Fellow of the Royal Society of Edinburgh. His proposers were Magnus Pyke, Andrew Phillipson, Sir David Cuthbertson and John Andrew Crichton. He was for several years the treasurer of the Chemical Information Group of the Royal Society of Chemistry, and was an honorary Professor in Biological Sciences at the University of East Anglia from 1968 to 1984. He was awarded an honorary Doctor of Science (ScD) from the University of East Anglia in 1977, and an honorary doctorate from the Faculty of Mathematics and Science at Uppsala University, Sweden in 1980.
== Overview of technique == Freeze branding can permanently alter the color of a mammal's coat, leaving the branded area white for the rest of its life. This is ultimately caused by the formation of ice crystals within melanocytes, the cells that normally coat the hair shaft with pigment as the growth root pushes the hair out of the follicle. This ice physically disrupts the microtubules along which melanin granules are transported from within the cell to its membrane, where they normally undergo exocytosis. That cellular machinery is permanently damaged after the cells thaw, preventing the surviving melanocytes from ever again secreting melanin. Most melanocytes rapidly fall into apoptosis and fail to regenerate. There are two types of freeze branding, one requiring a longer application of the brand than the other. Pigmented animals may be branded more quickly than pale animals because dark coats require only the hair follicles' pigmentation apparatus to be destroyed. This causes the branded skin to regrow hair to which no pigment has been applied as it leaves the hair sheath, rendering the shaft microscopically clear and macroscopically white. Pale animals require a longer branding time to kill the deepest part of the follicle, which secretes the hair shaft itself. This prevents any hair regrowth, leaving a bald patch of skin generally darker than the animal's coat. Freeze branding thereby ensures high contrast even on white-coated animals. The difference in branding time between the two methods is minimal, often separated by only a few seconds.
=== Differential diagnosis === To diagnose PMOS, other conditions must first be ruled out. These include thyroid disease (assessed via thyroid stimulating hormone), hyperprolactinemia (assessed via prolactin), and non-classic congenital adrenal hyperplasia (tested via 17-hydroxy progesterone). For those without any periods whatsoever or more severe signs or symptoms, further tests are recommended to exclude hypogonadotropic hypogonadism, any androgen-producing tumors or Cushing's disease. Overt virilisation (development of male sex characteristics) is not characteristic of PMOS and indicates that another underlying condition may be responsible.
Further development yielded β-lactamase-resistant penicillins, including flucloxacillin, dicloxacillin, and methicillin. These were significant for their activity against β-lactamase-producing bacterial species, but were ineffective against the MRSA strains. Another development of the line of penicillins was the antipseudomonal penicillins, such as carbenicillin, ticarcillin, and piperacillin, useful for their activity against Gram-negative bacteria. The usefulness of the β-lactam ring was such that related antibiotics, including the mecillinams, the carbapenems and, most important, the cephalosporins, still retain it at the centre of their structures.
=== Chips === EM351 integrates a programmable ARM Cortex-M 3 processor, IEEE 802.15.4 RF transceiver, 128kB of Flash, 12 KB RAM, and the EmberZNet PRO network protocol stack which supports the Zigbee PRO Feature Set. EM357 incorporates the features of the EM351 but has 192 KB of Flash for applications that require more memory. EM250 SoC combines a radio transceiver with a 16-bit XAP2 microprocessor. It has embedded mesh networking software, on-chip debugging, 128kB of Flash and 5kB of RAM. It was designed for applications that require long battery life, low external component count, and a reliable networking solution. EM260 Co-Processor combines a radio transceiver with a flash-based microprocessor. The interface allows application development with any microcontroller and tool-chain. Like the EM250 it was designed for applications that require long battery life, low external component count, and a reliable networking solution. EM2420 was the first chip Ember created. It has since become obsolete and has been replaced by second and third generation Ember chips.
Sources: en.wikipedia.org
== Function == Osteocalcin is secreted solely by osteoblasts and is thought to play a role in the body's metabolic regulation. In its carboxylated form, calcium is bound directly to the bone and thus concentrates here. In its uncarboxylated form, osteocalcin acts as a hormone in the body, signalling in the pancreas, fat, muscle, testes, and brain.
=== Bath salts === Magnesium sulfate is used in bath salts, especially for foot baths to soothe sore feet. The reason for the inclusion of the salt is partially cosmetic: the increase in ionic strength prevents some of the temporary skin wrinkling (partial maceration) which would occur with plain water baths. Epsom salt baths have been claimed to also soothe and hasten recovery of muscle pain, soreness, or injury. However, these claims have not been scientifically confirmed. The solubility of magnesium sulfate water is inhibited by lipids in lotions resulting in variable absorption rates when applied to the skin. Temperature and concentration are also factors.
=== 1979 === January 1: The United States and China normalize diplomatic relations. January 7: Vietnam deposes the Khmer Rouge and installs a pro-Vietnam, pro-Soviet government known as the People's Republic of Kampuchea. January 16: The Iranian Revolution ousts the pro-Western Shah, Mohammed Reza Pahlavi, and installs a theocracy under Grand Ayatollah Ruhollah Khomeini. The Central Treaty Organization dissolves as a result. February 17: Sino-Vietnamese War, China launches a punitive attack on Vietnam to punish it for invading Cambodia February 22: Saint Lucia becomes independent from the UK. February 24: A war broke out between Yemen Arab Republic and South Yemen. May 4: Margaret Thatcher is elected Prime Minister of the United Kingdom, becoming the first female to lead a major Western democracy. May 9: Civil war breaks out in El Salvador between Marxist-led insurgents and the U.S.-backed government. June 2: Pope John Paul II begins his first pastoral visit to his native Poland. June 18: U.S. President Jimmy Carter and Soviet leader Leonid Brezhnev sign the SALT II agreement, outlining limitations and guidelines for nuclear weapons. July 3: President Carter signs the first directive for financial aid to opponents of the pro-Soviet regime in Kabul, Afghanistan. July 16: Saddam Hussein becomes President of Iraq after Ahmed Hassan al-Bakr steps down. July 17: Marxist-led Sandinista revolutionaries overthrow the U.S.-backed Somoza dictatorship in Nicaragua. The Contra insurgency begins shortly thereafter.
=== As a drug target === The YAP1 oncogene serves as a target for the development of new cancer drugs. Small compounds have been identified that disrupt the YAP1-TEAD complex or block the binding function of WW domains. These small molecules represent lead compounds for the development of therapies for cancer patients, who harbor amplified or overexpressed YAP oncogene.
The nasolabial flap can be either superiorly based or inferiorly based; of which the superiorly based flap is the more practical rhinoplastic application, because it has a more versatile arc of rotation, and the donor-site scar is inconspicuous. Depending upon how the defect lay upon the nose, the flap pedicle-base can be incorporated either solely to the nasal reconstruction, or it can be divided into a second stage procedure. The blood supply for the flap pedicle are the transverse branches of the contralateral angular artery (the facial artery terminus parallel to the nose), and by a confluence of blood vessels from the angular artery and from the supraorbital artery in the medial canthus, (the angles formed by the meeting of the upper and lower eyelids). Therefore, the incisions for harvesting the nasolabial flap do not continue superiorly beyond the medial canthal tendon. The nasolabial flap is a random flap that is emplaced with the proximal (near) portion resting upon the lateral wall of the nose, and the distal (far) portion resting upon the cheek, which contains the main angular artery, and so is perfused with retrograde arterial flow.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.